Nebenwirkungen · Tamiflu
Tamiflu 30 mg hard capsules Tamiflu 45 mg hard capsules Tamiflu 75 mg hard capsules · Abschnitt 4.8 · PDF-Seite 11
HOS-110051 · Präparat HOS-093293
In patients with influenza who were receiving Tamiflu, there have been postmarketing reports of convulsions and delirium (including symptoms such as altered level of consciousness, confusion, abnormal behaviour, delusions, hallucinations, agitation, anxiety, nightmares), in a very few cases resulting in self-injury or fatal outcomes. These events were reported primarily among paediatric and adolescent patients and often had an abrupt onset and rapid resolution. The contribution of Tamiflu to those events is unknown. Such neuropsychiatric events have also been reported in patients with influenza who were not taking Tamiflu.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T13:27:00Z · SHA-256 49e3275593869eab140681f5cba3d7da7ff895500b27bac431ac12de5f5745b2 · Passage 782d350ef0bfbe7976fabc1071c58781cf215a311c7ee8136af0b6b564c2cd24 · Zeichen 10129–10759 im Abschnitt